An impressive quarter of growth, driven by CTPs in the US, single-use NPWT globally and a solid performance for Advanced Dressings.

For Q219, according to BioMedGPS’ SmartTRAK Financial Dashboard, WW Advanced Wound Care (AWC) revenues for Advanced Dressings, External Devices and Biologics was up +6.2% YoY. Acelity remained the AWC market leader, while Advanced Dressings saw strong growth from Mölnlycke and Coloplast, offset by weak performance from Smith & Nephew and ConvaTec. The total market reached...

Among the many topics covered in theQ219 Advanced Wound Care Market Recap* are:

SmartTRAK analysts Susan Paquette and Lennart Stadler on European market trends and emerging products and technologies showcased at EWMA 2019.

In many ways, the European Wound Management Association (EWMA) annual meeting is a microcosm of the latest wound care trends in Europe and provides a glimpse of what’s on the horizon in the worldwide (WW) market for Advanced Wound Care (AWC).

Dr. Ronald Baxter of Baylor University and Spectral MD, discusses the Spectral MD DeepView Wound Imaging System in predicting DFU wound healing utilizing artificial intelligence in an interview with SmartTRAK.

Spectral MD has developed the DeepView Wound Imaging System to utilize real-time data and artificial intelligence to predict wound healing. The Company has seen initial success in burn treatment and is now moving into validation of their system for diabetic foot ulcers (DFUs) with the goal to predict a wound’s healing potential at the initial clinical visit.

To learn more about Spectral MD’s multi-spectral imaging system, DeepView; the pilot DFU study to analyze the predictive qualities of its artificial intelligence deep learning program, and the company’s plans moving forward; SmartTRAK interviewed Dr. Ronald Baxter, of Baylor University and Spectral MD.

A transcript of SmartTRAK’s interview with Dr. Baxter is below. To view the interview recorded live at SAWC Spring 2019, click on the following video.

IRVINE, CALIF. (PRWEB) MAY 13, 2019

BioMedGPS is excited to host its subscribers and guests on Tuesday, June 4th, at a very special Pre-EWMA 2019 event at Gothenburg’s Universeum Aquarium.

SmartTRAK will be hosting an exclusive Private Event Pre-EWMA at Gothenburg’s Universeum Aquarium. Guests will be treated to an aquarium tour, dinner and briefing on the latest Trends, Opportunities and Innovations in Advanced Wound Care.

SmartTRAK’s Advanced Wound Care Experts will serve as panelists. Susan Paquette - SmartTRAK VP & General Manager, Wound - will be providing overall insights on the wound market and Lennart Stadler - SmartTRAK Senior Analyst, Advanced Wound Care - will be presenting data on important trends and innovations.

SmartTRAK, the leading source of competitive intelligence used by the top ten global orthopedic & wound care companies, was cited as a source in 3M's presentation "3M to Acquire Acelity Inc." published on May 2.

SmartTRAK talks with Raoul Verheggen, Global Product Director for DSM Biomedical, regarding the Company’s recent foray into the wound care space and how its addressing unmet needs for patients and businesses

Novel materials and components are key to innovative wound care products that provide superior patient outcomes. DSM Biomedical is a B2B supplier whose business it is to provide these unique components to the medical device industry. SmartTRAK talks with Raoul Verheggen of DSM Biomedical, Global Product Director for Wound, about the company, their capabilities and plans moving forward in support of wound care. A transcript of the interview is below. To listen to the interview recorded via Uberconference, click on the following video. 

SmartTRAK highlights the latest research on Sigvaris SECURE presented at SAWC Fall

A novel hybrid compression garment offers promise for patients with difficult-to-treat chronic edema according to an 11-patient case series presented at SAWC Fall. Patients with chronic edema, including lymphedema, are challenged in finding compression garments that are clinically efficacious, cosmetically appealing and comfortable to wear. The 11-patient case series evaluated Sigvaris’ recently launched SECURE, an innovative new Compression and Containment Hybrid (CCH) garment that combines the comfort of circular knit garments and the stiffness traditionally provided by thicker textiles, inelastic wraps or flat knit garments. The new hybrid circular knit garments are thin, cosmetically appealing, and meet the clinical requirement of chronic edema management – graduated compression and containment.

Dressings recover Q418, all segments showing solid gains

For FY18, according to BioMedGPS’ SmartTRAK Financial Dashboard, WW Advanced Wound Care (AWC) revenues for Advanced Dressings, External Devices and Biologics were up +4.1% YoY. Acelity remains the global market leader followed by S&N and Mölnlycke. Advanced Dressings, the workhorse of Advanced Wound Care, accounts for 52.3% of WW revenues, up +3.3% YoY. Skin/Dermal Substitute (CTP) revenue was up +10.7% YoY, lower than previous years, but still double-digit gains. WW NPWT was up +4.3% YoY, with traditional devices having a slight uptick and single-use driving the increase of +28.9%.

Among the many topics covered in the Q418/FY18 Advanced Wound Care Market Recap are:

S&N plans to shore up its Advanced Wound Bioactives business with the acquisition of Osiris Therapeutics but the deal may be in question as Osiris shareholders challenge the price.

 Smith & Nephew (S&N) announced on March 12, 2019 that it has agreed to acquire Osiris Therapeutics for $660MM with the deal expected to close Q219. However, the deal could be in question as a group of Osiris shareholders is suing to block the acquisition. The lawsuit disputes Cantor Fitzgerald’s discounted cash flow analysis, saying it does not adequately reflect Osiris’s future growth prospects, and is based on growth rates that are about half of what Osiris has experienced in recent years, resulting in a valuation that is too low. The acquisition would add the Osiris’s Grafix and Stravix product lines to S&N’s ailing Advanced Wound Bioactives portfolio. If allowed to proceed, the acquisition would solidify S&N’s leadership in wound biologics and changes the competitive landscape in the Advanced Wound Care market.